Why Prognos?

Prognos aggregates, harmonizes and analyzes clinical diagnostic data for life sciences, diagnostic companies, and payers, aiming to improve health by tracking and predicting disease. The Prognos Registry of 15 billion clinical records for 180 million patients in over 40 disease areas enables earlier identification of patients who can benefit from enhanced treatment decision-making, risk management, and quality improvement. During its research and development phase as Medivo, Prognos invested in innovations exploring the potential of clinical diagnostic assets and is now realizing the full value of those assets through advanced analytics with over 500 proprietary and learning clinical algorithms.

Market Opportunity

Prognos generates revenue through targeting and analytics services. Based on current monetization strategies, the addressable healthcare analytics market for Prognos’ products is estimated to reach $10.8 billion.

(Visited 1,300 times, 2 visits today)

Company Milestones

  • Medivo acquires Physicians Wellness Network (PWN)
  • Medivo launches free mobile and web-based app for hereditary angiodema
  • Medivo acquires mobile health startup WellApps
  • Medivo acquires diabetes management app OnTrack
  • Medivo partners with NeoGenomics Laboratories to expand Medivo's Lab Value Exchange (LVX) database
  • Medivo forms laboratory data liscensing agreement with Quest Diagnostics (NYSE:DGX)
  • Medivo launches CareInsights Dx analytics solutions to help payers better manage risk and improve quality
  • Medivo changes its name to Prognos

Eradicating disease by driving decisions earlier in healthcare.